Cambrex Corp. (CBM) Tops Q4 EPS by 7c, Revenues Miss; Offers FY19 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Cambrex Reports Fourth Quarter and Full Year 2018 Financial Results
February 13, 2019 6:40 AM EST- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base -
- Conference call at 8:30 a.m. ET on February 13, 2019 -
EAST RUTHERFORD, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading provider of development, manufacturing, testing and technology services for small molecules, reports results for the fourth quarter and full year ended December 31, 2018.
Fourth Quarter 2018 Highlights
Announced the acquisition of Avista Pharma Solutions (Avista), an early clinical phase Contract Development,... More